Capricor Therapeutics, Inc.
CAPR
Rank in Stocks
#11383
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which... Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (βDMDβ), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Share Price
$9.85
Last synced: 2026-11-09
Market Cap
$570.43M
Change (1 day)
9.44%
Change (1 year)
58.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Capricor Therapeutics, Inc. (CAPR)
Category
Healthcare
EPS for Capricor Therapeutics, Inc. (CAPR)
EPS as of June 2026 TTM: $-2.45
According to Capricor Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-2.45. At the end of 2025 the company had an EPS of $-2.26, a decrease compared to its 2024 EPS of $-1.15.
EPS history for Capricor Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.45 | 8.41% |
| 2025 | $-2.26 | 96.52% |
| 2024 | $-1.15 | 38.55% |
| 2023 | $-0.83 | -29.66% |
| 2022 | $-1.18 | 35.63% |
| 2021 | $-0.87 | -1.14% |
| 2020 | $-0.88 | -57.28% |
| 2019 | $-2.06 | -60.15% |
| 2018 | $-5.17 | -617.00% |
| 2017 | $1.00 | -109.86% |
| 2016 | $-10.14 | 25.34% |
| 2015 | $-8.09 | 52.35% |
| 2014 | $-5.31 | -37.31% |
| 2013 | $-8.47 | 303.33% |
| 2012 | $-2.10 | -96.79% |
| 2011 | $-65.43 | -30.21% |
| 2010 | $-93.75 | -39.34% |
| 2009 | $-154.56 | -43.21% |
| 2008 | $-272.15 | -10.49% |
| 2007 | $-304.06 | 220.06% |
| 2006 | $-95.00 | 660.61% |
| 2005 | $-12.49 | 4.34% |
| 2004 | $-11.97 | 11.87% |
| 2003 | $-10.70 | 3.68% |
| 2002 | $-10.32 | -30.13% |
| 2001 | $-14.77 | -44.39% |
| 2000 | $-26.56 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -739.18% |
US
|
|
| $-7.07 | 188.57% |
US
|
|
| $-5.29 | 115.92% |
AU
|
|
| $12.88 | -625.72% |
BE
|
|
| $21.56 | -980.00% |
NL
|
Questions about Capricor Therapeutics, Inc.'s earnings per share (EPS)
What is Capricor Therapeutics, Inc.'s earnings per share (EPS)?
Capricor Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-2.45, as of Jun 2026.
What was Capricor Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Capricor Therapeutics, Inc.'s earnings per share (EPS) was $-2.26, compared with $-1.15 in 2024.
How has Capricor Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Capricor Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($-0.83) and lowest in 2025 ($-2.26).
How does Capricor Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Capricor Therapeutics, Inc.'s earnings per share (EPS) ($-2.45) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.